Investigation of DNA damage response and apoptotic gene methylation pattern in sporadic breast tumors using high throughput quantitative DNA methylation analysis technology

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Pal, Ranjana ^a   Srivastava, Niloo ^a   Chopra, Rupali ^a   Gochhait, Sailesh ^a   Gupta, Pawan ^b   Prakash, Neeraj ^c   Agarwal, Gaurav ^d   Bamezai, Rameshwar N K ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

^b Dharamshila Narayana Superspeciality Hospital and Research Centre   (India)

^c RAJIV GANDHI CANCER INSTITUTE AND RESEARCH CENTRE   (India)

^d SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA2 PROTEIN; CASPASE 8; CHECKPOINT KINASE 2; DEATH RECEPTOR 4; DEATH RECEPTOR 5; BRCA1 PROTEIN; PROTEIN SERINE THREONINE KINASE; TNFRSF10A PROTEIN, HUMAN; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; BREAST TUMOR; CARCINOGENESIS; CORRELATION ANALYSIS; CPG ISLAND; DNA DAMAGE; DNA METHYLATION; DNA POLYMORPHISM; DNA REPAIR; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; QUANTITATIVE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; ADULT; AGED; FEMALE; GENETICS; GENOTYPE; IN VITRO STUDY; MASS SPECTROMETRY; MIDDLE AGED; POLYMERASE CHAIN REACTION; STATISTICAL MODEL;

ADULT; AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CASPASE 8; DNA METHYLATION; FEMALE; GENOTYPE; HUMANS; MASS SPECTROMETRY; MIDDLE AGED; MODELS, STATISTICAL; POLYMERASE CHAIN REACTION; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 78549286363     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-303     Document Type: Article

References (63)

1. Xu X, Gammon MD, Zhang Y, Bestor TH, Zeisel SH, Wetmur JG, Wallenstein S, Bradshaw PT, Garbowski G, Teitelbaum SL, et al. BRCA1 promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat 2009, 115:397-404. 10.1007/s10549-008-0075-5, 2693263, 18521744.
2. Russo J, Yang X, Hu YF, Bove BA, Huang Y, Silva ID, Tahin Q, Wu Y, Higgy N, Zekri A, Russo IH. Biological and molecular basis of human breast cancer. Front Biosci 1998, 3:D944-960.
3. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004, 4:143-153. 10.1038/nrc1279, 14732866.
4. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat Rev Cancer 2006, 6:107-116. 10.1038/nrc1799, 16491070.
5. Oldenburg RA, Meijers-Heijboer H, Cornelisse CJ, Devilee P. Genetic susceptibility for breast cancer: how many more genes to be found?. Crit Rev Oncol Hematol 2007, 63:125-149. 10.1016/j.critrevonc.2006.12.004, 17498966.
6. Gochhait S, Bukhari SI, Bairwa N, Vadhera S, Darvishi K, Raish M, Gupta P, Husain SA, Bamezai RN. Implication of BRCA2 -26G > A 5' untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg > Pro polymorphism. Breast Cancer Res 2007, 9:R71. 10.1186/bcr1780, 2242669, 17945002.
7. Saha A, Dhir A, Ranjan A, Gupta V, Bairwa N, Bamezai R. Functional IFNG polymorphism in intron 1 in association with an increased risk to promote sporadic breast cancer. Immunogenetics 2005, 57:165-171. 10.1007/s00251-005-0783-5, 15900487.
8. Saha A, Gupta V, Bairwa NK, Malhotra D, Bamezai R. Transforming growth factor-beta1 genotype in sporadic breast cancer patients from India: status of enhancer, promoter, 5'-untranslated-region and exon-1 polymorphisms. Eur J Immunogenet 2004, 31:37-42. 10.1111/j.1365-2370.2004.00442.x, 15009180.
9. Pal R, Gochhait S, Chattopadhyay S, Gupta P, Prakash N, Agarwal G, Chaturvedi A, Husain N, Husain SA, Bamezai RN. Functional implication of TRAIL -716 C/T promoter polymorphism on its in vitro and in vivo expression and the susceptibility to sporadic breast tumor. Breast Cancer Res Treat 2010,
10. Darvishi K, Sharma S, Bhat AK, Rai E, Bamezai RN. Mitochondrial DNA G10398A polymorphism imparts maternal Haplogroup N a risk for breast and esophageal cancer. Cancer Lett 2007, 249:249-255. 10.1016/j.canlet.2006.09.005, 17081685.
11. Saha A, Bairwa NK, Ranjan A, Gupta V, Bamezai R. Two novel somatic mutations in the human interleukin 6 promoter region in a patient with sporadic breast cancer. Eur J Immunogenet 2003, 30:397-400. 10.1111/j.1365-2370.2003.00423.x, 14675392.
12. Gochhait S, Bhatt A, Sharma S, Singh YP, Gupta P, Bamezai RN. Concomitant presence of mutations in mitochondrial genome and p53 in cancer development - a study in north Indian sporadic breast and esophageal cancer patients. Int J Cancer 2008, 123:2580-2586. 10.1002/ijc.23817, 18792899.
13. Srivastava N, Gochhait S, Gupta P, Bamezai RN. Copy number alterations of the H2AFX gene in sporadic breast cancer patients. Cancer Genet Cytogenet 2008, 180:121-128. 10.1016/j.cancergencyto.2007.09.024, 18206537.
14. Gochhait S, Dar S, Pal R, Gupta P, Bamezai RN. Expression of DNA damage response genes indicate progressive breast tumors. Cancer Lett 2009, 273:305-311. 10.1016/j.canlet.2008.08.009, 18805634.
15. Veeck J, Esteller M. Breast cancer epigenetics: from DNA methylation to microRNAs. J Mammary Gland Biol Neoplasia 2010, 15:5-17. 10.1007/s10911-010-9165-1, 20101446.
16. Stanssens P, Zabeau M, Meersseman G, Remes G, Gansemans Y, Storm N, Hartmer R, Honisch C, Rodi CP, Bocker S, van den Boom D. High-throughput MALDI-TOF discovery of genomic sequence polymorphisms. Genome Res 2004, 14:126-133. 10.1101/gr.1692304, 314289, 14707174.
17. Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, Xinarianos G, Cantor CR, Field JK, van den Boom D. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci USA 2005, 102:15785-15790. 10.1073/pnas.0507816102, 1276092, 16243968.
18. Ehrich M, Turner J, Gibbs P, Lipton L, Giovanneti M, Cantor C, van den Boom D. Cytosine methylation profiling of cancer cell lines. Proc Natl Acad Sci USA 2008, 105:4844-4849. 10.1073/pnas.0712251105, 2290817, 18353987.
19. Radpour R, Kohler C, Haghighi MM, Fan AX, Holzgreve W, Zhong XY. Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array. Oncogene 2009, 28:2969-2978. 10.1038/onc.2009.149, 19503099.
20. Radpour R, Haghighi MM, Fan AX, Torbati PM, Hahn S, Holzgreve W, Zhong XY. High-throughput hacking of the methylation patterns in breast cancer by in vitro transcription and thymidine-specific cleavage mass array on MALDI-TOF silico-chip. Mol Cancer Res 2008, 6:1702-1709. 10.1158/1541-7786.MCR-08-0262, 19010818.
21. Flanagan JM, Cocciardi S, Waddell N, Johnstone CN, Marsh A, Henderson S, Simpson P, da Silva L, Khanna K, Lakhani S, et al. DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status. Am J Hum Genet 2010, 86:420-433. 10.1016/j.ajhg.2010.02.008, 2833389, 20206335.
22. Ehrich M, Field JK, Liloglou T, Xinarianos G, Oeth P, Nelson MR, Cantor CR, van den Boom D. Cytosine methylation profiles as a molecular marker in non-small cell lung cancer. Cancer Res 2006, 66:10911-10918. 10.1158/0008-5472.CAN-06-0400, 17108128.
23. Ordway JM, Budiman MA, Korshunova Y, Maloney RK, Bedell JA, Citek RW, Bacher B, Peterson S, Rohlfing T, Hall J, et al. Identification of novel high-frequency DNA methylation changes in breast cancer. PLoS One 2007, 2:e1314. 10.1371/journal.pone.0001314, 2117343, 18091988.
24. Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jonsson G, Olsson H, Borg A, Ringner M. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res 2010, 12:R36. 10.1186/bcr2590, 2917031, 20565864.
25. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008, 8:782-798. 10.1038/nrc2465, 18813321.
26. Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 2007, 39:1462-1475. 10.1016/j.biocel.2007.02.007, 17403612.
27. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008, 7:1001-1012. 10.1038/nrd2637, 18989337.
28. Solier S, Pommier Y. The apoptotic ring: a novel entity with phosphorylated histones H2AX and H2B and activated DNA damage response kinases. Cell Cycle 2009, 8:1853-1859.
29. Solier S, Sordet O, Kohn KW, Pommier Y. Death receptor-induced activation of the Chk2- and histone H2AX-associated DNA damage response pathways. Mol Cell Biol 2009, 29:68-82. 10.1128/MCB.00581-08, 2612481, 18955500.
30. Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell 2007, 28:739-745. 10.1016/j.molcel.2007.11.015, 18082599.
31. Meek DW. Tumour suppression by p53: a role for the DNA damage response?. Nat Rev Cancer 2009, 9:714-723.
32. Ravi R, Bedi A. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Cancer Res 2002, 62:4180-4185.
33. Ray S, Shyam S, Fraizer GC, Almasan A. S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells. Mol Cancer Ther 2007, 6:1368-1378. 10.1158/1535-7163.MCT-05-0414, 17431115.
34. Liu X, Yue P, Khuri FR, Sun SY. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res 2004, 64:5078-5083. 10.1158/0008-5472.CAN-04-1195, 15289308.
35. Takimoto R, El-Deiry WS. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000, 19:1735-1743. 10.1038/sj.onc.1203489, 10777207.
36. Kuribayashi K, Krigsfeld G, Wang W, Xu J, Mayes PA, Dicker DT, Wu GS, El-Deiry WS. TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol Ther 2008, 7:2034-2038.
37. Fukazawa T, Fujiwara T, Uno F, Teraishi F, Kadowaki Y, Itoshima T, Takata Y, Kagawa S, Roth JA, Tschopp J, Tanaka N. Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells. Oncogene 2001, 20:5225-5231. 10.1038/sj.onc.1204673, 11526513.
38. Zhivotovsky B, Kroemer G. Apoptosis and genomic instability. Nat Rev Mol Cell Biol 2004, 5:752-762. 10.1038/nrm1443, 15340382.
39. Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, Lane WS, McMahon SB. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 2006, 24:841-851. 10.1016/j.molcel.2006.11.026, 1766330, 17189187.
40. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004, 73:39-85. 10.1146/annurev.biochem.73.011303.073723, 15189136.
41. Yang Q, Kiernan CM, Tian Y, Salwen HR, Chlenski A, Brumback BA, London WB, Cohn SL. Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome. Clin Cancer Res 2007, 13:3191-3197. 10.1158/1078-0432.CCR-06-2846, 17545522.
42. van Noesel MM, van Bezouw S, Salomons GS, Voute PA, Pieters R, Baylin SB, Herman JG, Versteeg R. Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res 2002, 62:2157-2161.
43. Shivapurkar N, Toyooka S, Toyooka KO, Reddy J, Miyajima K, Suzuki M, Shigematsu H, Takahashi T, Parikh G, Pass HI, et al. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer 2004, 109:786-792. 10.1002/ijc.20041, 14999791.
44. Kang JH, Kim SJ, Noh DY, Park IA, Choe KJ, Yoo OJ, Kang HS. Methylation in the p53 promoter is a supplementary route to breast carcinogenesis: correlation between CpG methylation in the p53 promoter and the mutation of the p53 gene in the progression from ductal carcinoma in situ to invasive ductal carcinoma. Lab Invest 2001, 81:573-579.
45. Cucer N, Taheri S, Ok E, Ozkul Y. Methylation status of CpG islands at sites -59 to +96 in exon 1 of the BRCA2 gene varies in mammary tissue among women with sporadic breast cancer. J Genet 2008, 87:155-158. 10.1007/s12041-008-0023-5, 18776644.
46. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005, 23:9067-9072. 10.1200/JCO.2004.01.0454, 16172462.
47. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 2008, 9:465-476. 10.1038/nrg2341, 18463664.
48. Ushijima T, Watanabe N, Shimizu K, Miyamoto K, Sugimura T, Kaneda A. Decreased fidelity in replicating CpG methylation patterns in cancer cells. Cancer Res 2005, 65:11-17.
49. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006, 7:21-33. 10.1038/nrg1748, 16369569.
50. Laird PW. Principles and challenges of genome-wide DNA methylation analysis. Nat Rev Genet 2010, 11:191-203. 10.1038/nrg2732, 20125086.
51. Cotter TG. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 2009, 9:501-507. 10.1038/nrc2663, 19550425.
52. Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 2008, 9:231-241. 10.1038/nrm2312, 18073771.
53. O'Driscoll M, Jeggo PA. The role of double-strand break repair - insights from human genetics. Nat Rev Genet 2006, 7:45-54. 10.1038/nrg1746, 16369571.
54. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004, 4:592-603. 10.1038/nrc1412, 15286739.
55. Li D, Da L, Tang H, Li T, Zhao M. CpG methylation plays a vital role in determining tissue- and cell-specific expression of the human cell-death-inducing DFF45-like effector A gene through the regulation of Sp1/Sp3 binding. Nucleic Acids Res 2008, 36:330-341. 10.1093/nar/gkm1028, 2248752, 18033804.
56. Zelko IN, Mueller MR, Folz RJ. CpG methylation attenuates Sp1 and Sp3 binding to the human extracellular superoxide dismutase promoter and regulates its cell-specific expression. Free Radic Biol Med 2010, 48:895-904. 10.1016/j.freeradbiomed.2010.01.007, 20079429.
57. Veeck J, Esteller M. Breast cancer epigenetics: from DNA methylation to microRNAs. J Mammary Gland Biol Neoplasia 2010, 15:5-17. 10.1007/s10911-010-9165-1, 2824126, 20101446.
58. Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L, Pai R, Hymowitz SG, Ashkenazi A. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 2005, 280:2205-2212. 10.1074/jbc.M410660200, 15520016.
59. Wu J. Apoptosis and angiogenesis: two promising tumor markers in breast cancer (review). Anticancer Res 1996, 16:2233-2239.
60. Fernandez Y, Gu B, Martinez A, Torregrosa A, Sierra A. Inhibition of apoptosis in human breast cancer cells: role in tumor progression to the metastatic state. Int J Cancer 2002, 101:317-326. 10.1002/ijc.10628, 12209955.
61. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001, 411:342-348. 10.1038/35077213, 11357141.
62. Kalari S, Pfeifer GP. Identification of driver and passenger DNA methylation in cancer by epigenomic analysis. Adv Genet 2010, 70:277-308. full_text, 20920752.
63. Ramchandani S, Bhattacharya SK, Cervoni N, Szyf M. DNA methylation is a reversible biological signal. Proc Natl Acad Sci USA 1999, 96:6107-6112. 10.1073/pnas.96.11.6107, 26843, 10339549.